[Pathophysiology and therapeutic aspects of left ventricular "remodeling" in the post-infarct phase]

J Auer1, R Berent, B Eber

  • 1II. Interne Abteilung mit Kardiologie und Internistischer Intensivmedizin, A. ö. Krankenhaus Wels, Grieskirchnerstrasse 42, A-4600 Wels. johann.auer@khwels.at

Acta Medica Austriaca
|January 5, 2002
PubMed

Insights

Left ventricular remodeling alters heart size and function after injury. Early interventions can mitigate damage and improve long-term outcomes in conditions like myocardial infarction.

Area of Science:

  • Cardiology
  • Physiology
  • Pathology

Context:

  • Left ventricular remodeling is a complex process influenced by mechanical, neurohormonal, and genetic factors.
  • It can be adaptive during normal growth or pathological in conditions such as myocardial infarction, cardiomyopathy, hypertension, and valvular heart disease.
  • Postinfarction remodeling occurs in early (within 72 hours) and late phases, involving infarct expansion, ventricular dilatation, shape distortion, and hypertrophy.

Purpose:

  • To describe the mechanisms and phases of left ventricular remodeling.
  • To highlight the adaptive responses and triggers involved in myocardial repair.
  • To emphasize the role of infarct artery patency and pharmacological interventions in managing remodeling.

Summary:

  • Left ventricular remodeling involves changes in size, shape, and function regulated by various factors.
  • Early postinfarction remodeling includes infarct expansion, potentially leading to rupture or aneurysm.
  • Late remodeling involves global ventricular changes, hypertrophy, and collagen degradation, influenced by infarct artery patency.

Impact:

  • Understanding remodeling aids in developing strategies to prevent adverse cardiac events.
  • Pharmacological interventions like ACE inhibitors and beta-blockers can minimize adverse remodeling and improve prognosis.
  • Targeting infarct artery patency is crucial for managing postinfarction remodeling and cardiac repair.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...